These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 36198171)

  • 21. RET kinase inhibitors for
    Vodopivec DM; Hu MI
    Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting RET alterations in cancer: Recent progress and future directions.
    Shabbir A; Kojadinovic A; Shafiq T; Mundi PS
    Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
    Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
    Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precision oncology with selective RET inhibitor selpercatinib in
    Gouda MA; Subbiah V
    Ther Adv Med Oncol; 2023; 15():17588359231177015. PubMed ID: 37360768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
    Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
    Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
    Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
    Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
    Le D; Konda B
    Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
    Chen MF; Repetto M; Wilhelm C; Drilon A
    Drugs; 2024 Sep; 84(9):1035-1053. PubMed ID: 38997570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
    Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
    J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
    Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T
    Front Oncol; 2021; 11():704084. PubMed ID: 34497761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
    Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
    J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
    Addeo A; Miranda-Morales E; den Hollander P; Friedlaender A; O Sintim H; Wu J; Mani SA; Subbiah V
    Pharmacol Ther; 2023 Feb; 242():108344. PubMed ID: 36632846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current perspectives on the management of patients with advanced
    Elisei R; Grande E; Kreissl MC; Leboulleux S; Puri T; Fasnacht N; Capdevila J
    Front Oncol; 2023; 13():1141314. PubMed ID: 37207147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
    Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
    Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pralsetinib treatment for multiple
    Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
    J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State-of-the-Art Strategies for Targeting
    Subbiah V; Yang D; Velcheti V; Drilon A; Meric-Bernstam F
    J Clin Oncol; 2020 Apr; 38(11):1209-1221. PubMed ID: 32083997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan.
    Fukuda N; Tanizawa Y; Nakamura K; Okada Y; Segall G; Kiiskinen U; Fasnacht N; Sanderson I; Rider A; Lewis K
    Future Oncol; 2023 May; 19(16):1125-1137. PubMed ID: 37278236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
    Hegde A; Andreev-Drakhlin AY; Roszik J; Huang L; Liu S; Hess K; Cabanillas M; Hu MI; Busaidy NL; Sherman SI; Dadu R; Grubbs EG; Ali SM; Lee J; Elamin YY; Simon GR; Blumenschein GR; Papadimitrakopoulou VA; Hong D; Meric-Bernstam F; Heymach J; Subbiah V
    ESMO Open; 2020 Oct; 5(5):e000799. PubMed ID: 33097651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
    Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
    J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.